Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase
β Scribed by L. R. Whitfield; R. H. Stern; A. J. Sedman; R. Abel; D. M. Gibson
- Publisher
- Springer-Verlag
- Year
- 2000
- Tongue
- English
- Weight
- 513 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0378-7966
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
SUMMARY Pyrrole-ring labeled \(\left[{ }^{14} \mathrm{C}\right]\) atorvastatin (Lipitor 8 , CI-981), [ \(\left.\mathrm{R}-\left(\mathrm{R}^{*}, \mathrm{R}^{*}\right)\right]-2-\) (4-fluorophenyl)- \(\beta, \gamma\)-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-[3- \(\left.{ }^{14}
The absorption and disposition of fluvastatin have been studied in the female rabbit. In naive rabbits receiving a single oral dose (1 mg kg-I) of [3H]fluvastatin, absorption was rapid and amounted to c. 90 per cent compared with an intravenous reference dose. The drug was subject to considerable fi
## Abstract A new synthetic method for the preparation of pitavastatin is described. The approach circumvents various synthetic problems associated with the buildup of the 3,5βdihydroxyβC~7~ acid side chain of HMGβCoA reductase inhibitors (statins). The use of the C~6~βamide derivative **5** instea
On p. 1074, in Scheme 3, the correct formula of NK-104 should be as follows: 2) On p. 1077, line 16 should read as follows: (390 ml) was cooled to Γ 788, and 1.6m BuLi in hexane (374.4 g, 881 mmol) was added under 3) On p. 1078, line 15 should read as follows: As HPLC revealed the presence of mor